Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-09-14 02:01 UTC

BIOMED PULSE

Monday, September 14, 2026 — Daily Briefing on Longevity, Viruses & New Cures

⚡ TL;DR

The Bundibugyo virus Ebola outbreak in the Democratic Republic of the Congo is now the largest Ebola outbreak ever recorded, having expanded to 61 health zones across six provinces as of September 10, 2026. The overall mood is grave on the outbreak front and cautiously productive in longevity research, where senescence-targeting biomaterials are advancing rapidly.

🦠 OUTBREAKS & VIRUSES

BUNDIBUGYO VIRUS DISEASE (EBOLA) — DRC AND UGANDA, ACTIVE AND INTENSIFYING

  • As of September 10, 2026, the Bundibugyo virus disease (BVD) outbreak in the DRC has expanded to 61 health zones, adding Kayna in North Kivu since the August 28 update. [1]
  • Affected provinces now number six out of 26 in the DRC: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, and Tshopo, with cross-border transmission to Uganda still documented. [1]
  • WHO designated this the largest Ebola outbreak ever reported in the DRC, expanding faster than any prior Ebola outbreak; as of July 1, 2026, cumulative confirmed cases had already reached 1,460 with 452 deaths. [2]
  • By July 15, 2026, the toll had risen to 2,124 confirmed cases and 828 deaths, reflecting a case fatality rate among confirmed cases exceeding 39 percent. [3]
  • The outbreak originated in Mongbwalu Health Zone, Ituri Province, first identified on May 5, 2026, when high-mortality illness including deaths among health workers was flagged to WHO. [4]

ANIMAL RABIES — UNITED STATES

  • CDC issued a statement on September 10, 2026 noting increases in recent animal rabies activity and associated human exposures across the United States. [5]
  • Travelers and communities are urged to avoid contact with wildlife and ensure domestic animal vaccinations are current. [5]

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP, MULTI-COUNTRY (ONGOING BACKGROUND)

  • WHO's fifth Disease Outbreak News on the Andes hantavirus outbreak linked to the M/V Hondius cruise ship was published July 2, 2026, following the original notification of severe acute respiratory illness onboard on May 2, 2026. [6]
  • The last CDC hantavirus response transcript on record is dated June 24, 2026, indicating continued active monitoring of this multi-country cluster. [7]

YELLOW FEVER — AMERICAS AND AFRICA

  • WHO reported January through May 26, 2026 data showing six countries reported 79 human yellow fever infections; transmission activity carried over from an elevated 2025 season in the Americas. [8]
  • Infected Aedes and Haemagogus mosquitoes remain the transmission vector; vaccination before travel to endemic areas is the primary preventive tool. [8]

NIPAH VIRUS — KERALA, INDIA

  • On June 11, 2026, Kerala State confirmed one laboratory-confirmed Nipah virus (NiV) infection in Kozhikode district; the adult male developed neurological symptoms and was hospitalized June 10, 2026. [9]
  • No secondary cases were reported in that update, but NiV carries a high case fatality rate and close contact tracing was initiated immediately. [9]

MEASLES — BANGLADESH

  • As of April 23, 2026, Bangladesh notified WHO of a nationwide measles surge affecting 58 of 64 districts across all eight divisions, with 19,161 suspected cases and 2,897 laboratory-confirmed cases. [10]

WEST NILE VIRUS — UNITED STATES

  • CDC flagged an early and record West Nile virus season as of July 1, 2026, urging Americans to use mosquito repellent and protective clothing through the summer season.

CYCLOSPORA — TACO BELL, FIVE STATES

  • By July 17, 2026, shredded iceberg lettuce served at Taco Bell locations was confirmed as the source of Cyclospora cayetanensis infections across five states, with 1,644 people sickened.
  • The outbreak had since expanded to four additional states as of July 24, 2026.

🧬 LONGEVITY & AGING

SENOLYTIC AND SENESCENCE-TARGETING THERAPIES

  • Researchers published in Biomaterials (July 14, 2026) on injectable hydrogel microspheres loaded with senescence-targeting apoptotic extracellular vesicles that reduced ferroptosis in nucleus pulposus cells, pointing toward a biomaterial strategy against intervertebral disc degeneration.
  • A separate Bioactive Materials study (July 31, 2026) demonstrated that combining antioxidant and epigenetic interventions in a dual-modal approach attenuated the self-perpetuating senescence cycle in osteoarthritis joint tissue.

BONE AGING AND REPAIR

  • A dual-targeting mRNA lipid nanoparticle designed to restore ABCA1-dependent cholesterol homeostasis was reported in Bioactive Materials (August 20, 2026) to promote repair of age-related bone defects in preclinical models.
  • A Bioactive Materials paper (August 4, 2026) found that loss of EGFR signaling activity in skeletal stem and progenitor cells is mechanistically associated with impaired fracture healing in aged mice, suggesting EGFR as a therapeutic target.
  • A quercetin-derived carbon dot nanocomposite hydrogel incorporating M2 macrophage-derived migrasomes was reported August 30, 2026 to regenerate osteoporotic bone defects in a microenvironment-responsive manner.

ALZHEIMER'S DISEASE AND BRAIN AGING

  • Young plasma-derived exosomes, engineered for enhanced potency, were reviewed in Bioactive Materials (August 15, 2026) for their therapeutic potential in Alzheimer's disease, with proposed mechanisms including clearance of amyloid aggregates and restoration of synaptic signaling.
  • A broad Bioactive Materials review (August 5, 2026) catalogued exosome mechanisms across multiple brain diseases, emphasizing their blood-brain barrier crossing capacity and cargo delivery potential.

LUNG CANCER AND AGING IN ASIA

  • A study published in Annals of Medicine (September 11, 2026) projected the shifting burden of tracheal, bronchus, and lung cancer in aging Asian populations to 2050, identifying population aging as a key structural driver of rising incidence rates across the region.

DEPRESCRIBING IN OLDER ADULTS

  • A Lancet Healthy Longevity commentary called for a rationale-first framework in deprescribing trials before selecting trial design, arguing that the mechanism and goal of reducing medications in older adults must drive methodology choices.

ANESTHESIA FOR HIP FRACTURE IN OLDER PATIENTS

  • A multicenter randomized clinical trial published in Lancet Healthy Longevity compared spinal versus general anesthesia in older German patients undergoing hip fracture surgery, a high-mortality procedure in the elderly, with results informing perioperative risk reduction strategies.

NAD+ MEASUREMENT VALIDATION TRIAL

  • ClinicalTrials.gov (updated September 11, 2026, NCT07416786) lists an active study validating nicotinamide adenine dinucleotide (NAD+) measurement via magnetic resonance spectroscopy (MRS) in healthy adults before and after nicotinamide riboside (NR) supplementation, a key step for aging biomarker standardization.

MULTI-COMPONENT NUTRITION AND OLDER ADULT FUNCTION

  • A ClinicalTrials.gov study (NCT07815158, updated September 11, 2026) is evaluating a 12-week multi-component nutritional formula's effects on WHO Integrated Care for Older People (ICOPE) intrinsic capacity domains, physical function, and metabolic biomarkers in community-dwelling older adults.

💊 NEW CURES & APPROVALS

ETCAMAH (CAMIZESTRANT) — ASTRAZENECA PHARMACEUTICALS, LP

  • AstraZeneca received an original FDA approval (NDA220359) for Etcamah, containing camizestrant, a next-generation oral selective estrogen receptor degrader (SERD) intended for breast cancer treatment.

HYRNUO (SEVABERTINIB) — BAYER HEALTHCARE

  • Bayer Healthcare received a supplemental FDA approval (NDA219972) for Hyrnuo, containing sevabertinib, a targeted kinase inhibitor in the oncology space.

IBRUTINIB GENERIC — HETERO LABS LTD V

  • Hetero Labs Ltd received an original ANDA approval (ANDA211182) for a generic formulation of ibrutinib, the BTK inhibitor used widely in blood cancers including chronic lymphocytic leukemia.

BRIVARACETAM GENERIC — ZHEJIANG JUTAI PHARMACEUTICAL

  • Zhejiang Jutai received an original ANDA approval (ANDA220136) for generic brivaracetam, an antiseizure medication that works as a synaptic vesicle protein 2A (SV2A) ligand.

LACOSAMIDE GENERIC — REGCON HOLDINGS

  • Regcon Holdings received a supplemental ANDA approval (ANDA208308) for generic lacosamide, another antiepileptic agent with a sodium channel-stabilizing mechanism.

AMELUZ (AMINOLEVULINIC ACID HCL) — BIOFRONTERA

  • Biofrontera received a supplemental FDA approval (NDA208081) for Ameluz, a photosensitizer used with photodynamic therapy for actinic keratosis and superficial skin lesions.

🧪 CLINICAL TRIALS

AML COMBINATION THERAPY — GILTERITINIB, VENETOCLAX, AZACITIDINE

  • ClinicalTrials.gov study NCT05520567 (updated September 11, 2026) is testing gilteritinib plus venetoclax plus azacitidine in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) patients, targeting a population for whom standard chemotherapy is less effective.

MDS/MPN — PACRITINIB (CSF1R/IRAK1/JAK2/FLT3 INHIBITOR)

  • NCT06303193 (updated September 11, 2026) is evaluating pacritinib in adults and adolescents aged 12 and older with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms, diseases that carry elevated risk in older populations and can progress to AML.

PARKINSON'S DISEASE — VIRTUAL REALITY COGNITIVE REHABILITATION

  • The OPERA study (NCT06920511, updated September 11, 2026) is a single-arm pilot evaluating the PRoBio bio-cooperative robotic platform for cognitive rehabilitation in Parkinson's disease patients with mild cognitive impairment.

NAD+ VALIDATION — NICOTINAMIDE RIBOSIDE SUPPLEMENTATION

  • NCT07416786 (updated September 11, 2026) aims to standardize NAD+ measurement methodology using MRS in healthy adults before and after NR supplementation, a prerequisite for reliable aging intervention trials.

OLDER ADULT NUTRITION AND INTRINSIC CAPACITY

  • NCT07815158 (updated September 11, 2026) is a 12-week interventional study on multi-component nutritional formulas in community-dwelling older adults, measuring ICOPE-domain outcomes and metabolic biomarkers.

ROCURONIUM ONSET IN PATIENTS AGED 80 AND OLDER

  • NCT06681662 (updated September 11, 2026) is testing whether ephedrine 0.15 mg/kg shortens rocuronium onset time in patients aged 80 or older undergoing surgery, addressing a practical anesthesia gap in the very elderly.

📢 PUBLIC HEALTH

CDC RABIES ACTIVITY ALERT

  • CDC issued a formal statement on September 10, 2026 warning of increased animal rabies activity and elevated human exposure incidents across the United States; communities should report sick wildlife immediately. [5]

OBESITY PREVALENCE — 23 STATES ABOVE 35 PERCENT

  • CDC data from 2023 showed that in 23 states, more than one in three adults has obesity; before 2013 no state had reached a 35 percent prevalence threshold.

DRUG OVERDOSE DEATHS DECLINING

  • Provisional 2024 data from CDC's National Vital Statistics System showed a 27 percent decrease in drug overdose deaths, building on a nearly 24 percent decline reported in early 2025.

KINDERGARTEN VACCINATION COVERAGE — SLIGHT DECLINE

  • CDC data released August 17, 2026 showed kindergarten vaccination rates remain high overall, but coverage dropped 0.1 percent, a signal public health officials are watching in the context of ongoing measles activity.

WORLD TRADE CENTER HEALTH PROGRAM — 25 YEARS

  • CDC published a paper on September 10, 2026 examining 9/11-related health outcomes and lessons learned from the World Trade Center Health Program over 25 years, including chronic respiratory and oncologic sequelae.

BIOMED PULSE is an informational briefing only. Nothing herein constitutes medical advice. Consult qualified healthcare professionals for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus - Democratic Republic… — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  3. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  4. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  5. CDC Statement on Increases in Recent Animal Rabies Activity an… — CDC Newsroom
  6. Hantavirus outbreak linked to cruise ship travel, Multi-locations — WHO Disease Outbreak News
  7. Transcript - Update on CDC's Hantavirus Response - 6/24/26 — CDC Newsroom
  8. Yellow fever - Global — WHO Disease Outbreak News
  9. Nipah virus disease - India — WHO Disease Outbreak News
  10. Measles - Bangladesh — WHO Disease Outbreak News

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260914-02-v75 · 2026-09-14 02:01 UTC · pulse.uzylab.com

Read next